Beximco Pharmaceuticals Statistics

Total Valuation

Beximco Pharmaceuticals has a market cap or net worth of BDT 37.92 billion. The enterprise value is 45.08 billion.

Market Cap	37.92B
Enterprise Value	45.08B

Important Dates

The next estimated earnings date is Monday, January 27, 2025.

Earnings Date	Jan 27, 2025
Ex-Dividend Date	n/a

Share Statistics

Beximco Pharmaceuticals has 446.11 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	446.11M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	4.07%
Owned by Institutions (%)	3.86%
Float	297.34M

Valuation Ratios

The trailing PE ratio is 6.37.

PE Ratio	6.37
Forward PE	n/a
PS Ratio	0.84
PB Ratio	0.76
P/TBV Ratio	0.86
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 4.37, with an EV/FCF ratio of 8.11.

EV / Earnings	7.57
EV / Sales	1.00
EV / EBITDA	4.37
EV / EBIT	5.28
EV / FCF	8.11

Financial Position

The company has a current ratio of 2.43, with a Debt / Equity ratio of 0.09.

Current Ratio	2.43
Quick Ratio	0.62
Debt / Equity	0.09
Debt / EBITDA	0.48
Debt / FCF	0.89
Interest Coverage	7.75

Financial Efficiency

Return on equity (ROE) is 11.66% and return on invested capital (ROIC) is 9.18%.

Return on Equity (ROE)	11.66%
Return on Assets (ROA)	7.61%
Return on Capital (ROIC)	9.18%
Revenue Per Employee	40.06M
Profits Per Employee	5.31M
Employee Count	1,122
Asset Turnover	0.64
Inventory Turnover	1.82

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -41.86% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-41.86%
50-Day Moving Average	79.24
200-Day Moving Average	100.24
Relative Strength Index (RSI)	56.01
Average Volume (20 Days)	760,485

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Beximco Pharmaceuticals had revenue of BDT 44.95 billion and earned 5.96 billion in profits. Earnings per share was 13.35.

Revenue	44.95B
Gross Profit	19.91B
Operating Income	8.54B
Pretax Income	7.67B
Net Income	5.96B
EBITDA	10.23B
EBIT	8.54B
Earnings Per Share (EPS)	13.35

Full Income Statement

Balance Sheet

The company has 1.74 billion in cash and 4.94 billion in debt, giving a net cash position of -3.20 billion or -7.17 per share.

Cash & Cash Equivalents	1.74B
Total Debt	4.94B
Net Cash	-3.20B
Net Cash Per Share	-7.17
Equity (Book Value)	53.60B
Book Value Per Share	111.25
Working Capital	13.28B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 7.35 billion and capital expenditures -1.79 billion, giving a free cash flow of 5.56 billion.

Operating Cash Flow	7.35B
Capital Expenditures	-1.79B
Free Cash Flow	5.56B
FCF Per Share	12.47

Full Cash Flow Statement

Margins

Gross margin is 44.29%, with operating and profit margins of 18.99% and 13.25%.

Gross Margin	44.29%
Operating Margin	18.99%
Pretax Margin	17.06%
Profit Margin	13.25%
EBITDA Margin	22.76%
EBIT Margin	18.99%
FCF Margin	12.38%

Dividends & Yields

This stock pays an annual dividend of 4.00, which amounts to a dividend yield of 4.71%.

Dividend Per Share	4.00
Dividend Yield	4.71%
Dividend Growth (YoY)	14.29%
Years of Dividend Growth	n/a
Payout Ratio	26.64%
Buyback Yield	n/a
Shareholder Yield	4.71%
Earnings Yield	15.71%
FCF Yield	14.67%

Dividend Details

Stock Splits

The last stock split was on November 26, 2020. It was a forward split with a ratio of 1.1.

Last Split Date	Nov 26, 2020
Split Type	Forward
Split Ratio	1.1

Scores

Beximco Pharmaceuticals has an Altman Z-Score of 3.86.

Altman Z-Score	3.86
Piotroski F-Score	n/a